Goodwin Biotechnology is collaborating with RAFAGEN
Goodwin Biotechnology, Inc. is a fully integrated contract manufacturer of monoclonal antibodies and vaccines; Goodwin Biotechnology has the experience and expertise in development of recombinant proteins and antibody drug conjugates.
Goodwin Biotechnology has almost 20 years of experience in the field of biotechnology whereas RAFAGEN, Inc. is a well known leader in cell line engineering for protein monoclonal antibody drug production; RAFAGEN's main aim is the development and commercialization of next generation gene expression systems.
PhD, Soo Young Lee, Senior vice president of Goodwin Biotechnology Inc. expressed that by collaborating with RAFAGEN for cell line engineering they can expand their horizons and capabilities as biological contract manufacturing company.
Both the companies recently announced their collaboration agreement for the cell line engineering and biological contract manufacturing.
